Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative
Leonardo De Luca1, Marc P Bonaca2, Giulia Magnani3
1Department of Cardiosciences, A.O. San Camillo-Forlanini , Roma, Italy.
Insights
Optimal antithrombotic therapy for patients with both coronary artery disease (CAD) and peripheral artery disease (PAD) is crucial. Tailoring treatment intensity based on atherosclerotic burden improves cardiovascular outcomes in these high-risk individuals.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Patients with coexisting coronary artery disease (CAD) and peripheral artery disease (PAD) face high cardiovascular morbidity and mortality.
- Antithrombotic therapies can reduce adverse cardiovascular events in CAD or PAD patients.
- Optimal antithrombotic strategies for combined CAD and PAD are not well-established.
Purpose of the Study:
- To review current data on antithrombotic therapies for patients with CAD and lower extremity PAD.
- To provide insights into optimizing antithrombotic treatment in this high-risk population.
Main Methods:
- Systematic review of existing literature.
- Analysis of antithrombotic treatment regimens in CAD patients with concomitant lower extremity PAD.
Main Results:
- Antithrombotic response in lower extremity PAD varies with atherosclerotic burden.
- Less potent P2Y12 inhibitors like clopidogrel may suffice for isolated stable PAD.
- Lower extremity PAD patients with documented CAD benefit from more intensive antithrombotic treatment.
Conclusions:
- Treatment decisions for antithrombotic therapy in PAD patients should consider the extent of atherosclerosis.
- A tailored approach to antithrombotic therapy is necessary for patients with combined CAD and PAD.
- Further research is needed to define optimal antithrombotic regimens for this complex patient group.
Introduction:
Patients with coexisting coronary artery disease (CAD) and peripheral artery disease (PAD) present a very high rate of cardiovascular (CV) morbidity and mortality. Several studies have demonstrated that different regimens of antithrombotic therapies may reduce adverse CV events in patients with CAD or PAD. However, data on optimal antithrombotic combination to use in these very high-risk patients are scarce and conflicting.
Areas Covered:
This paper reviews current data on antithrombotic therapies tested in CAD patients with concomitant lower extremity PAD.
Expert Opinion:
The antithrombotic response in lower extremity PAD patients varies based on the atherosclerotic burden. For patients with isolated stable PAD may be sufficient a less potent P2Y12 inhibitor as clopidogrel, whereas patients with lower extremity PAD and documented CAD benefit from a more intense and prolonged antithrombotic treatment.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Atherosclerosis IV: Nursing Management
Venous Thrombosis IV: Nursing Management


